Carrick licenses targeted ovarian cancer drug from BTG
Dublin, Ireland-based biopharma Carrick Therapeutics has licensed exclusive globl rights to develop and commercialise BTG’s targeted ovarian cancer drug BTG945.
Read More
Tag: CT900
- NHS to offer fezolinetant for menopause‑related hot flushes and night‑sweats
- UCB reports superiority of bimekizumab in psoriatic arthritis study
- Kainova reports positive results for DT‑9081 in advanced solid tumours
- EnteroBiotix completes enrolment for trial of EBX‑102‑02
- Lundbeck completes patient randomisation early in global MSA trial
